305 related articles for article (PubMed ID: 25549697)
1. Effects of paliperidone extended release on functioning level and symptoms of patients with recent onset schizophrenia: An open-label, single-arm, flexible-dose, 12-months follow-up study.
Üçok A; Saka MC; Bilici M
Nord J Psychiatry; 2015 Aug; 69(6):426-32. PubMed ID: 25549697
[TBL] [Abstract][Full Text] [Related]
2. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I
Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of paliperidone ER in patients with unsatisfactorily controlled schizophrenia by other antipsychotics: a flexible-dose approach.
Mauri M; Mauri MC; Adami M; Reggiardo G; Giulio C
Int Clin Psychopharmacol; 2015 Nov; 30(6):329-37. PubMed ID: 26230269
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Safety of Paliperidone Extended Release in Adolescents with Schizophrenia: An Open-Label, Flexible Dose Study.
Savitz A; Lane R; Nuamah I; Singh J; Hough D; Gopal S
J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):548-57. PubMed ID: 26218669
[TBL] [Abstract][Full Text] [Related]
5. Switching to paliperidone extended release in patients with schizophrenia dissatisfied with previous olanzapine treatment: Post hoc analysis of an open-label, prospective study.
Si TM; Cai SL; Zhuo JM; Zhang LL
Medicine (Baltimore); 2019 Jan; 98(3):e13688. PubMed ID: 30653088
[TBL] [Abstract][Full Text] [Related]
6. Association between symptom control and functional improvement in patients with acute schizophrenia: A post hoc analysis of an open-label, single-arm, multi-center study of paliperidone-extended release formulation.
Si TM; Zhang YL; Feng Y; Zhuo JM; Cai S; Zhang L
Psychiatry Res; 2019 Apr; 274():301-305. PubMed ID: 30831454
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study.
Davidson M; Emsley R; Kramer M; Ford L; Pan G; Lim P; Eerdekens M
Schizophr Res; 2007 Jul; 93(1-3):117-30. PubMed ID: 17466492
[TBL] [Abstract][Full Text] [Related]
8. A prospective flexible-dose study of paliperidone palmitate in nonacute but symptomatic patients with schizophrenia previously unsuccessfully treated with oral antipsychotic agents.
Schreiner A; Bergmans P; Cherubin P; Keim S; Rancans E; Bez Y; Parellada E; Carpiniello B; Vidailhet P; Hargarter L
Clin Ther; 2014 Oct; 36(10):1372-88.e1. PubMed ID: 25444566
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of paliperidone extended release in adolescents with schizophrenia: a randomized, double-blind study.
Savitz AJ; Lane R; Nuamah I; Gopal S; Hough D
J Am Acad Child Adolesc Psychiatry; 2015 Feb; 54(2):126-137.e1. PubMed ID: 25617253
[TBL] [Abstract][Full Text] [Related]
10. Paliperidone extended-release tablets in patients with recently diagnosed schizophrenia.
Canuso CM; Bossie CA; Amatniek J; Turkoz I; Pandina G; Cornblatt B
Early Interv Psychiatry; 2010 Feb; 4(1):64-78. PubMed ID: 20199482
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of paliperidone extended-release in schizophrenia patients with prominent affective symptoms.
Canuso CM; Turkoz I; Sheehan JJ; Bossie CA
J Affect Disord; 2010 Jan; 120(1-3):193-9. PubMed ID: 19552963
[TBL] [Abstract][Full Text] [Related]
12. Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional study.
Schreiner A; Caspi A; Bergmans P; Cherubin P; Keim S; Lara E; Pinchuk I; Schuepbach D; Suleman S; Hargarter L
Psychopharmacology (Berl); 2017 Jan; 234(1):3-13. PubMed ID: 27815602
[TBL] [Abstract][Full Text] [Related]
13. Paliperidone extended-release for schizophrenia: effects on symptoms and functioning in acutely ill patients with negative symptoms.
Canuso CM; Bossie CA; Turkoz I; Alphs L
Schizophr Res; 2009 Aug; 113(1):56-64. PubMed ID: 19560322
[TBL] [Abstract][Full Text] [Related]
14. Retrospective Analysis of the Effectiveness and Tolerability of Long-Acting Paliperidone Palmitate Antipsychotic in Adolescent First-Episode Schizophrenia Patients.
Petrić D; Rački V; Gačo N; Kaštelan A; Graovac M
J Child Adolesc Psychopharmacol; 2019 Apr; 29(3):197-204. PubMed ID: 30758986
[TBL] [Abstract][Full Text] [Related]
15. Treatment of acute schizophrenia with paliperidone ER: predictors for treatment response and benzodiazepine use.
Heres S; Don L; Herceg M; Bidzan L; Blanc M; Siracusano A; Maciulis V; Lahaye M; Schreiner A
Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():207-12. PubMed ID: 24096139
[TBL] [Abstract][Full Text] [Related]
16. Effects of paliperidone extended release on the symptoms and functioning of schizophrenia.
Huang MW; Yang TT; Ten PR; Su PW; Wu BJ; Chan CH; Lan TH; Liu IC; Chiu WC; Li CY; Cheng KS; Yeh YC
BMC Clin Pharmacol; 2012 Jan; 12():1. PubMed ID: 22225965
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies.
Meltzer HY; Bobo WV; Nuamah IF; Lane R; Hough D; Kramer M; Eerdekens M
J Clin Psychiatry; 2008 May; 69(5):817-29. PubMed ID: 18466043
[TBL] [Abstract][Full Text] [Related]
18. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial.
Kane J; Canas F; Kramer M; Ford L; Gassmann-Mayer C; Lim P; Eerdekens M
Schizophr Res; 2007 Feb; 90(1-3):147-61. PubMed ID: 17092691
[TBL] [Abstract][Full Text] [Related]
19. Satisfaction of immediate or delayed switch to paliperidone palmitate in patients unsatisfied with current oral atypical antipsychotics.
Kwon JS; Kim SN; Han J; Lee SI; Chang JS; Choi JS; Lee HJ; Cho SJ; Jun TY; Lee SH; Han C; Lee KU; Lee KK; Lee E
Int Clin Psychopharmacol; 2015 Nov; 30(6):320-8. PubMed ID: 26196188
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study.
Savitz AJ; Xu H; Gopal S; Nuamah I; Ravenstijn P; Janik A; Schotte A; Hough D; Fleischhacker WW
Int J Neuropsychopharmacol; 2016 Jul; 19(7):. PubMed ID: 26902950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
